Article
Medicine, General & Internal
Jun Won Park, Min Jung Kim, Hyoun-Ah Kim, Jin Hyun Kim, Eun Bong Lee, Kichul Shin
Summary: Tapering the dose of TCZ after achieving low disease activity in patients with rheumatoid arthritis increases the risk of losing low disease activity without significant safety benefits.
FRONTIERS IN MEDICINE
(2022)
Article
Rheumatology
Mikkel Ostergaard, Ronald F. van Vollenhoven, Anna Rudin, Merete Lund Hetland, Marte Schrumpf Heiberg, Dan C. Nordstrom, Michael T. Nurmohamed, Bjorn Gudbjornsson, Lykke Midtboll Ornbjerg, Pernille Boyesen, Kristina Lend, Kim Horslev-Petersen, Till Uhlig, Tuulikki Sokka, Gerdur Grondal, Simon Krabbe, Joakim Lindqvist, Inger Gjertsson, Daniel Glinatsi, Meliha Crnkic Kapetanovic, Anna-Birgitte Aga, Francesca Faustini, Pinja Parmanne, Tove Lorenzen, Cagnotto Giovanni, Johan Back, Oliver Hendricks, Daisy Vedder, Tuomas Rannio, Emma Grenholm, Maud Kristine Ljosa, Eli Brodin, Hanne Lindegaard, Annika Soderbergh, Milad Rizk, Alf Kastbom, Per Larsson, Line Uhrenholt, Soren Andreas Just, David J. Stevens, Trine Bay Laurbjerg, Gunnstein Bakland, Inge Christoffer Olsen, Espen A. Haavardsholm, Jon Lampa, NORD-STAR Study Grp
Summary: This study compared the clinical and radiographic outcomes of different biological treatments with active conventional therapy in patients with early rheumatoid arthritis (RA). The results showed that abatacept and certolizumab pegol had higher clinical remission rates compared to active conventional therapy, while tocilizumab did not show significant differences. Radiographic progression was low and similar across treatments.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Paul Studenic, Daniel Aletaha, Maarten de Wit, Tanja A. Stamm, Farideh Alasti, Diane Lacaille, Josef S. Smolen, David T. Felson
Summary: This study aimed to externally validate a revised Boolean remission criteria using a higher patient global assessment (PtGA) threshold and validate the provisionally endorsed index-based criteria. The results showed that using the higher PtGA threshold increased the proportion of patients classified as achieving remission under the "Boolean2.0" criteria, improved agreement with index-based criteria, and did not compromise predictive value for radiographic or functional outcomes. The study findings were endorsed by ACR and EULAR.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Renske C. F. Hebing, Marry Lin, Maja Bulatovic Calasan, Ittai B. Muller, Sohaila Mahmoud, Sandra Heil, Eduard A. Struys, Bart J. F. van den Bemt, Jos W. R. Twisk, Willem Lems, Michael T. Nurmohamed, Gerrit Jansen, Robert de Jonge
Summary: This study investigates the pharmacokinetics of methotrexate polyglutamate (MTX-PG) accumulation in red blood cells (RBCs) and peripheral blood mononuclear cells (PBMCs) in patients with early rheumatoid arthritis (RA) after oral and subcutaneous MTX treatment. The results show that there are disparate pharmacokinetic profiles between PBMCs and RBCs, with higher accumulation of MTX-PG in PBMCs. The distribution profile of MTX-PG in PBMCs remains constant over 6 months, while in RBCs, the main PG-moiety changes from MTX-PG(1) to MTX-PG(3).
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Delila Singh, Nina Hesse, Alla Skapenko, Hendrik Schulze-Koops
Summary: Methotrexate is associated with rare bone lesions that are often misdiagnosed as osteoporotic fractures. Early diagnosis is crucial for treatment and prevention of further osteopathology. This case highlights the importance of raising awareness and taking appropriate therapeutic measures, including discontinuing methotrexate.
Article
Chemistry, Analytical
Junqing He, Junyan Wang, Min Zhang, Guoyue Shi
Summary: As a folate antagonist, methotrexate (MTX) has been widely used in clinics for treating various tumors and inflammatory diseases. However, the dosage and clearance of MTX vary between individuals, and it may cause life-threatening side effects at high doses. Therefore, a convenient and simple method for MTX sensing is highly demanded.
Article
Rheumatology
Clement Triaille, Gaelle Tilman, Tatiana Sokolova, Axelle Loriot, Joelle Marchandise, Stephanie De Montjoye, Adrien Nzeusseu-Toukap, Laurent Meric de Bellefon, Caroline Bouzin, Christine Galant, Patrick Durez, Bernard R. Lauwerys, Nisha Limaye
Summary: This study used transcriptomic profiling to explore clinically relevant subgroups in early, untreated rheumatoid arthritis (RA) patients. The synovial transcriptome closely mirrored clinical disease activity, and the ratio of M2:M1 macrophages was inversely correlated with inflammation and disease activity, suggesting a protective role for tissue resident macrophages in RA.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Claire Daien, Marek Krogulec, Paul Gineste, Jean-Marc Steens, Laurence Desroys du Roure, Sophie Biguenet, Didier Scherrer, Julien Santo, Hartmut Ehrlich, Patrick Durez
Summary: This study evaluated the safety and efficacy of ABX464 in patients with moderate-to-severe active rheumatoid arthritis. The results showed that ABX464 at a 50 mg dose was safe, well tolerated, and showed promising efficacy. The 100 mg dose had a high dropout rate due to gastrointestinal adverse events.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Siddharth Jain, Varun Dhir, Amita Aggarwal, Ranjan Gupta, Bidyalaxmi Leishangthem, Shankar Naidu, Aastha Khullar, Supriya Maurya, Veena Dhawan, Shefali Khanna Sharma, Aman Sharma, Sanjay Jain
Summary: This study compared the efficacy and safety of different dose escalation strategies of oral MTX in RA patients over a period of 16-24 weeks. The results showed that a faster escalation strategy was not more effective than the usual strategy, but was associated with higher gastrointestinal adverse events in the initial phase.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Multidisciplinary Sciences
Helen R. Gosselt, Costanza L. Vallerga, Pooja R. Mandaviya, Erik Lubberts, Johanna M. W. Hazes, Robert de Jonge, Sandra G. Heil
Summary: The study did not identify genome-wide significant differences as biomarkers for Methotrexate (MTX) therapy response, necessitating meta-analyses.
Article
Rheumatology
Ulf Lindstrom, Daniela di Giuseppe, Sofia Exarchou, Gerd-Marie Alenius, Tor Olofsson, Eva Klingberg, Lennart Jacobsson, Johan Askling, Johan K. Wallman
Summary: This study aimed to compare the treatment outcomes of patients with newly diagnosed psoriatic arthritis (PsA) and rheumatoid arthritis (RA) using methotrexate (MTX) monotherapy. The results showed that PsA patients were less likely to continue the use of MTX compared to RA patients, and the effectiveness of MTX was also lower in PsA.
Review
Pharmacology & Pharmacy
Gurleen Kour, Syed Assim Haq, Bijender Kumar Bajaj, Prem N. Gupta, Zabeer Ahmed
Summary: Phytochemicals have long been known for their therapeutic potential in autoimmune disorders such as rheumatoid arthritis, but their combination with DMARDs can increase the efficacy of treatment while reducing toxic side effects. Studies have shown promising results in experimental and clinical settings when combining phytochemicals with DMARDs, highlighting the importance of this approach in future RA therapy.
PHARMACOLOGICAL RESEARCH
(2021)
Review
Endocrinology & Metabolism
F. Robin, S. Cadiou, J-D Albert, G. Bart, G. Coiffier, P. Guggenbuhl
Summary: Methotrexate (MTX)-related osteopathy, characterized by pain, osteoporosis, and atypical fractures, is a rare condition that has been reported in patients treated with low doses of MTX for inflammatory diseases. Pathophysiological studies suggest a possible dose-dependent residual effect of MTX on osteo-forming bone cells.
OSTEOPOROSIS INTERNATIONAL
(2021)
Article
Rheumatology
Abdullah Ali Hadi Almayali, Maarten Boers, Linda Hartman, Daniela Opris, Reinhard Bos, Marc R. Kok, Jose A. P. Da Silva, Ed Griep, Ruth Klaasen, Cornelia F. Allaart, Paul Baudoin, Hennie G. Raterman, Zoltan Szekanecz, Frank Buttgereit, Pavol Masaryk, Willem Lems, Yvo Smulders, Maurizio Cutolo, Marieke M. ter Wee
Summary: The GLORIA trial investigated the effects of prednisolone 5 mg/day as an addition to standard care for 2 years in elderly patients with rheumatoid arthritis. Tapering off prednisolone moderately increased disease activity and risk of flare, but did not show evidence of adrenal insufficiency.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Chemistry, Physical
Genna Braverman, S. Louis Bridges, Larry W. Moreland
Summary: This article summarizes the current evidence base for biologic tapering in RA, outlines real-world outcomes findings, reviews important contextual factors relevant to therapy deescalation, such as cost-effectiveness considerations and patient perspectives, and concludes by summarizing current guidelines.
CURRENT OPINION IN COLLOID & INTERFACE SCIENCE
(2022)
Article
Rheumatology
Roy Fleischmann, Mark C. Genovese, Yong Lin, Gregory St John, Desiree van der Heijde, Sheldon Wang, Juan Jose Gomez-Reino, Jose Antonio Maldonado-Cocco, Marina Stanislav, Alan J. Kivitz, Gerd R. Burmester
Article
Rheumatology
Elena Nikiphorou, Sam J. Norton, Lewis Carpenter, David A. Walsh, Paul Creamer, Josh Dixey, Adam Young, Patrick D. W. Kiely
Article
Rheumatology
Lewis Carpenter, Elena Nikiphorou, Patrick D. W. Kiely, David A. Walsh, Adam Young, Sam Norton
Letter
Rheumatology
Carlos Sanchez-Piedra, Cesar Diaz-Torne, Javier Manero, Jose M. Pego-Reigosa, Inigo Rua-Figueroa, Miguel A. Gonzalez-Gay, Juan Gomez-Reino, Jose M. Alvaro-Gracia
ANNALS OF THE RHEUMATIC DISEASES
(2020)
Article
Rheumatology
Josef S. Smolen, Stanley B. Cohen, Hans-Peter Tony, Morton Scheinberg, Alan Kivitz, Andra Balanescu, Juan Gomez-Reino, Liyi Cen, Johann Poetzl, Tamas Shisha, Dmitrij Kollins
Summary: In the 52-week ASSIST-RA study, SDZ-RTX demonstrated similar B cell concentrations over time, efficacy, safety and immunogenicity to Ref-RTX.
Review
Rheumatology
Patrick D. W. Kiely, Mark E. Lloyd
Summary: Ankle arthritis is a useful indicator in the diagnosis of rheumatic diseases, typically caused by trauma. In cases of inflammatory mono/oligo arthritis involving the ankle, it is more likely to be undifferentiated arthritis or spondyloarthritis.
Article
Medicine, General & Internal
Manuel Pombo-Suarez, Jose Ramon Maneiro Fernandez, Juan Jesus Gomez-Reino
Summary: The study evaluated adherence to treatment in patients with rheumatoid arthritis in Spain, identifying predictors of adherence. The adherence rate was found to be suboptimal, with factors such as drug regimen convenience, number of medications, and living situation influencing adherence. Developing effective intervention strategies could improve adherence in this patient population.
PATIENT PREFERENCE AND ADHERENCE
(2021)
Article
Rheumatology
Manuel Pombo-Suarez, Carlos Sanchez-Piedra, Blanca Garcia-Magallon, Ana Perez-Gomez, Sara Manrique-Arija, Raquel Martin-Domenech, Maria Colazo, Cristina Campos, Jose Campos, Javier del Pino-Montes, Maria J. Arteaga, Luis Cea-Calvo, Federico Diaz-Gonzalez, Juan J. Gomez-Reino
Summary: This study found that the long-term retention rate of golimumab decreased over time in a real-world setting, with higher retention rates observed in patients using it as first-line therapy and in combination with methotrexate therapy.
CLINICAL RHEUMATOLOGY
(2021)
Article
Rheumatology
Sizheng Steven Zhao, Elena Nikiphorou, Adam Young, Patrick D. W. Kiely
Summary: In this study, it was found that large joints become progressively involved in patients with early rheumatoid arthritis (RA), with the wrist being most commonly affected followed by the ankle. The progression of the disease was similar between RF-negative and RF-positive cases. It is recommended to follow treat-to-target approaches regardless of RF status.
RHEUMATOLOGY INTERNATIONAL
(2022)
Article
Rheumatology
Onosi Sylvia Ifesemen, Daniel Frederick McWilliams, Sam Norton, Patrick D. W. Kiely, Adam Young, David Andrew Walsh
Summary: The study aims to describe the prevalence, risk factors, and longitudinal course of fatigue in early rheumatoid arthritis (RA) patients. The findings suggest that fatigue is common and persistent in early RA, and diverse characteristics indicative of central mechanisms are associated with persistent fatigue.
Review
Rheumatology
Denesh Srikantharajah, Mark E. Lloyd, Patrick D. W. Kiely
Summary: Autoantibodies to the PM/Scl nucleolar protein complex are associated with an overlap syndrome of systemic sclerosis and idiopathic inflammatory myopathy. This study describes the diverse clinical features in four cases with anti-PM/Scl-75 and/or anti-PM/Scl-100 antibodies, and highlights the efficacy of Rituximab and IVIg therapy in treating muscle weakness and oesophageal dysfunction.
RHEUMATOLOGY INTERNATIONAL
(2022)
Review
Medical Laboratory Technology
Kathryn Biddle, Matthew D. Taylor, Sarah E. Linstead, Patrick D. W. Kiely
Summary: In the past 40 years, 15 myositis-specific antibodies have been described and characterized. These antibodies are associated with specific clinical phenotypes and play an important role in the diagnosis and classification of idiopathic inflammatory myositis.
JOURNAL OF APPLIED LABORATORY MEDICINE
(2022)
Article
Rheumatology
Elena Nikiphorou, Hannah Jacklin, Ailsa Bosworth, Clare Jacklin, Patrick Kiely
Summary: Patients with rheumatoid arthritis not treated with advanced therapies experience significant difficulties in everyday life, including sleep problems, fatigue, and the need to change working hours. The study findings indicate that increasing difficulties with daily physical activities, reduced emotional and physical well-being are significantly associated with pain, number of flares, and ability to cope.
RHEUMATOLOGY ADVANCES IN PRACTICE
(2021)
Article
Rheumatology
Miguel Angel Abad Hernandez, Jose Luis Andreu, Alejandro Balsa Criado, Federico Diaz-Gonzalez, Jose Vicente Moreno Muelas, Ruben Queiro Silva, Juan J. Gomez-Reino
Summary: The Spanish Society of Rheumatology emphasizes its commitment to the sustainability of the health system and supports the advancement of new biosimilar drugs to enhance healthcare efficiency. In the context of increased therapeutic options, preserving the prescription freedom of physicians becomes crucial.
REUMATOLOGIA CLINICA
(2021)
Article
Rheumatology
Jon T. Giles, Alexis Ogdie, Juan J. Gomez Reino, Philip Helliwell, Rebecca Germino, Lori Stockert, Pamela Young, Wael Joseph, Rajiv Mundayat, Daniela Graham, Christopher Ritchlin
Summary: This study investigated the impact of body mass index (BMI) on tofacitinib efficacy and safety in patients with PsA, and found that at month 3, tofacitinib demonstrated higher efficacy compared to placebo, but some efficacy measures were reduced in patients with baseline BMI >= 35.